HISTORY OF ESCOZINE FOR PETS™

2. PETLIFE™ - White Paper HISTORY OF ESCOZINE FOR PETS™ Table of Contents I. Escozine For Pets™ verses Escozul / Vidatox ....................................................................... 2 II. Patent ................................................................................................................................................ 2 III. Labiofam ........................................................................................................................................... 2 IV. Location / Natural Habitat of the Caribbean Blue Scorpion ................................................ 3 V. Confirmation from Atheris Laboratory, Switzerland ............................................................. 4 VI. Summary .......................................................................................................................................... 5 (310) 279-5154 info@petlifepharma.com www.petlifepharma.com The information contained in this document is subject to national and International Copyright© laws and is the proprietary and exclusive property of PetLife Pharmaceuticals, except as otherwise indicated. No part of this document, in whole or in part, may be reproduced, stored, transmitted, or used for design purposes without the prior written permission of PetLife Pharmaceuticals. The information contained in this document is subject to change without notice. The information in this document is provided for informational purposes only. Privacy Information: This document may contain information of a sensitive nature. This information should not be given to persons other than those who are involved with PetLife Pharmaceuticals, or who will become involved during the lifecycle. History of Escozine For Pets™ 2014 1

3. PETLIFE™ - White Paper A NEW CANCER FORMULATION DERIVED FROM BLUE SCORPION VENOM. I. Escozine For Pets™ verses Escozul / Vidatox PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the world which have the patented formulation based upon blue scorpion venom. Medolife’s Escozine is the first alternative natural medication recognized for oncological treatments by the Ministry of Health, Food and Drug Administration, of the Dominican Republic. PetLife owns the exclusive rights to all veterinary uses of the patented formulation and technology. Although based on the same Blue Scorpion venom compound, Escozine™ and Escozine for Pets™ have many advantages over Escozul and Vidatox which are illustrated below in the history and comparison of the products. Patent II. PetLife owns exclusive veterinary rights to Arthur Mikaelian’s patent which achieved a full patent in 2012 for the bioactive peptide (Blue Scorpion Venom) and polarization technology (Patent # US 8,097,284 B2). This unique patented polarization technique escalates the highly positive charges in the extracellular membrane of main compounds in Escozine For Pets™. This gives them the ability to function as a transportation mechanism; it also intensifies the binding preferences with malignant cells. The Patented Mikaelian Polarization technology plays an essential role in potentiating the Blue Scorpion Venom and delivering more active ingredients directly into cancerous cells in comparison to non-polarized ingredients. This technology allows fewer compounds to be used and allows large scale commercialization of the natural version. PetLife’s exclusively owned bioactive peptide (Blue Scorpion Venom) and polarization technology for veterinary use is the base for a novel pharmacologically active compound which is critical in numerous new generation essential drugs and Nutraceuticals for veterinary use. III. Labiofam The Cuban laboratory, Labiofam, has no registration, patent or completed scientific research regarding Escozul to make an adequately supported presentation of this product to a regulatory agency or, for that matter, to the public. Further, actual production quality control for medication of ESCOZUL does not exist at this time. Labiofam has completely stopped the production of Escozul and it has been replaced by Vidatox, which is a homeopathic version which has been diluted 1:1,000. We have a spectrophotometer analysis of Vidatox which shows no evidence of venom. The website, www.escozul-cancer.com, contains useful technical and scientific information regarding Escozul. However, it also simultaneously posts misleading History of Escozine For Pets™ 2014 2

4. PETLIFE™ - White Paper information alleging (with noticeable exaggeration) that Labiofam is the “only” company who is entitled to engage in the research and production of Escozul. In fact, the Guantanamo group as specifically mentioned in this website is the original group who initiated the blue scorpion medication project. The former leader was Michel Bordier, the scientist who discovered the effect of blue scorpion venom. The Guantanamo group has more case studies and experience with blue scorpion venom than Labiofam. However, the Guantanamo group is presented on the website as a company who does not possess the right or knowledge to conduct research and development of Escozul. Dr. Mikaelian was present and indeed witnessed Labiofam doctors employing statistical analyses and protocols created by the Guantanamo group. After the death of Michel Bordier, the Guantanamo group stopped being active and they lost their position as a leading research group. Michel Bordier did not apply for any patent or any legal registration or claims. This is only one of many distortions of the real facts regarding the origin, development and sale of Escozul. Collectively these distortions appear to be an actively orchestrated propaganda campaign to promote Labiofam as the only legitimate provider of Escozul. Beyond the obvious, it would appear these misrepresentations benefit the tourist economy of Cuba. Since Labiofam was not free to market its product internationally and was not prepared to meet the demands of ongoing production and distribution, significant numbers of tourists used to travel to Cuba to receive the medication, under the false belief that it is free. The actual cost of Escozul under these circumstances was prohibitive for most of the general public, who have need of it. IV. Location / Natural Habitat of the Caribbean Blue Scorpion Another significant misstatement made on the website is that the blue scorpions only inhabit the island of Cuba. Medolife has scientific proof that proves that this is false. A scorpion which is identical to the Cuban blue scorpion has been confirmed to inhabit the Dominican Republic. The technical name of the Cuban blue scorpion is Rhopalurus junceus (Buthidae family); and the technical name of the Dominican blue scorpion is Rhopalurus princeps (also Buthidae family). Cuban biologists Armas and Prendini have confirmed that these scorpions are of the same species. Additionally, this has been confirmed by Atheris Laboratory in Switzerland. Rhopalurus princeps, (Karsch, 1879) By: Michiel Cozijn “Morphological Information Rhopalurus princeps seems more closely related to the Cuban Rhopalurus species (Prendini et al, 2009).” See http://www.ntnu.no/ub/scorpion-files/r_princeps_biography.pdf. History of Escozine For Pets™ 2014 3

5. PETLIFE™ - White Paper In 2007 Medolife signed a contract with the Ministry of Environment of Dominican Republic and started expeditions and located Rhopalurus princeps with local scientist and biologist Kelvin A. Guerrero. See Kelvin A. Guerrero’s. website: 2007-2011: Consultant Entomologist and Research Advisor for Medolife Corporation for the research: Investigation on the Biochemistry and Ecology of the Species of Scorpion of the Family Buthidae in the Dominican Republic in order to identify potential organic of the scorpion venom compound that can be beneficial to cure cancer disease on human. The source: http://kguerrero.net/consulting.html V. Confirmation from Atheris Laboratory, Switzerland In 2009, the venom of Rhopalurus junceus (Cuban blue scorpion) and the venom of Rhopalurus princeps (Dominican Republic blue scorpion) were sent by Medolife to Switzerland's world famous Atheris laboratory (http://atheris.com) for identification of these two venoms. (As background, Atheris laboratory helped Trans-molecular Inc. to identify Chlorotoxin, one of the main components in Buthidae family scorpion venom. See the following links to obtain more details and information regarding this study. http://en.wikipedia.org/wiki/Chlorotoxin and http://www.transmolecular.com) Atheris Laboratory has provided scientific confirmation to Medolife that both scorpion venoms block sodium and potassium volt gate channels. (Please read letter reprinted below from Atheris.) This action causes actual shrinkage of tumors and inhibits cancer cell proliferation. Interestingly, the report (MALDI-TOF-MS) analyses from Atheris laboratory indicates that Dominican blue scorpion venom has a three times higher concentration of Chlorotoxin, which is one of the main components with anti tumoral properties and also has smaller molecular weight than the Cuban blue scorpion venom, which makes Escozine For Pets™ more effective in the penetration of cancer cell membranes and more therapeutic compound passes through the blood–brain barrier (BBB). History of Escozine For Pets™ 2014 4

6. PETLIFE™ - White Paper The following is a copy of the letter from Atheris Laboratory: <See the original letter attached> Dear Arthur Grant Mikaelian PhD, Please find attached both certificates of analysis concerning Rhopalurus princeps and R. junceus. These analyses allowed the detection of numerous components in both venoms. Spectra clearly display signals that are consistent with scorpion venoms with two major sets of masses, the first one located around 3-4 kDa (mainly potassium channel inhibitors) and the second one at 6-8 kDa (mostly sodium channel inhibitors). We hope these analyses correspond to your expectations. Best regards, Philippe Favreau 03/30/2010 Philippe Favreau Atheris Laboratories CP 314 1233 Bernex - Geneva Tel: 0041 22 850 05 85 Fax: 0041 22 850 05 86 PetLife note: The “two certificates’ referenced directly contain information deemed proprietary and are not included in this White Paper. Select prospective partners or investors may be granted access to the certificates, for due diligence purposes, under NDA. VI. Summary Dr. Mikaelian is currently the only scientist who has completed all research and the development process and has attained the legal registration to commercialize the Blue Scorpion venom based product. This patent and technology has been licensed to PetLife Pharmaceuticals for commercialization. Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals. PetLife’s sister company, Medolife, owns and markets the human product, Escozine. The product, Escozul, is not produced or sold by Medolife and neither Medolife nor PetLife rely on this product in any way. History of Escozine For Pets™ 2014 5

7. PETLIFE™ - White Paper PetLife in association with Medolife has its own independent source of Blue Scorpion venom in the Dominican Republic and has established the world’s first Scorpion reservation which is 50,000 square meters and can produce millions of doses to meet global demand. History of Escozine For Pets™ 2014 6

8. PETLIFE™ - White Paper History of Escozine For Pets™ 2014 7